Literature DB >> 29153599

LPS-induced cortical kynurenic acid and neurogranin-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning.

A Oliveros1, K Wininger2, J Sens2, M K Larsson3, X C Liu3, S Choi1, A Faka3, L Schwieler3, G Engberg3, S Erhardt3, D S Choi4.   

Abstract

The N-Methyl-d-Aspartate receptor (NMDAR) antagonist kynurenic acid (KYNA) and the post-synaptic calmodulin binding protein neurogranin (Nrgn) have been implicated in neurological and neuropsychiatric conditions including Alzheimer's disease and schizophrenia. This study indicates that systemic dual-lipopolysaccharide (LPS) injections increases KYNA in the medial prefrontal cortex (mPFC), which is accompanied with increased phosphorylation of nuclear factor kappa chain of activated B cells (NFκB) and activation of the nuclear factor of activated T- cells (NFAT). Our results also indicate that dual-LPS increases Nrgn phosphorylation and concomitantly reduces phosphorylation of calmodulin kinase-II (CaMKII). We confirmed that systemic blockade of kynurenine-3 monooxygenase in conjunction with kynurenine administration results in significant increases in Nrgn phosphorylation and a significant reduction of CaMKII phosphorylation in the mPFC. Consequently, dual-LPS administration induced significant impairments in stimulus processing during Pavlovian conditioning. Taken together, our study indicates that elevations in KYNA in the mPFC can directly regulate NMDA-Nrgn-CaMKII signaling, suggesting that neuroinflammatory conditions affecting this pathway may be associated with cognitive dysfunction.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Kynurenic-acid; Lipopolysaccharide; Medial-prefrontal cortex; NFAT; Neurogranin; Ventral-hippocampus

Mesh:

Substances:

Year:  2017        PMID: 29153599      PMCID: PMC5728408          DOI: 10.1016/j.jneuroim.2017.09.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  85 in total

1.  Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding.

Authors:  Amy C Chess; David J Bucci
Journal:  Behav Brain Res       Date:  2006-04-18       Impact factor: 3.332

2.  Increased prefrontal cortex neurogranin enhances plasticity and extinction learning.

Authors:  Ling Zhong; Joshua Brown; Audra Kramer; Kanwardeep Kaleka; Amber Petersen; Jamie N Krueger; Matthew Florence; Matthew J Muelbl; Michelle Battle; Geoffrey G Murphy; Christopher M Olsen; Nashaat Z Gerges
Journal:  J Neurosci       Date:  2015-05-13       Impact factor: 6.167

Review 3.  Pavlovian conditioning and its proper control procedures.

Authors:  R A Rescorla
Journal:  Psychol Rev       Date:  1967-01       Impact factor: 8.934

4.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

5.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

6.  Conditioned taste aversion with lipopolysaccharide and peptidoglycan does not activate cytokine gene expression in the spleen and hypothalamus of mice.

Authors:  Cécile Mormède; Karine Palin; Keith W Kelley; Nathalie Castanon; Robert Dantzer
Journal:  Brain Behav Immun       Date:  2004-03       Impact factor: 7.217

7.  Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling.

Authors:  Hafiz Mohmmad Abdul; Michelle A Sama; Jennifer L Furman; Diana M Mathis; Tina L Beckett; Adam M Weidner; Ela S Patel; Irfan Baig; M Paul Murphy; Harry LeVine; Susan D Kraner; Christopher M Norris
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

8.  Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia.

Authors:  Ryan D Ward; Eleanor H Simpson; Vanessa L Richards; Gita Deo; Kathleen Taylor; John I Glendinning; Eric R Kandel; Peter D Balsam
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

9.  Effects of the neurogranin variant rs12807809 on thalamocortical morphology in schizophrenia.

Authors:  Jamie Yu Jin Thong; Anqi Qiu; Min Yi Sum; Carissa Nadia Kuswanto; Ta Ahn Tuan; Gary Donohoe; Yih Yian Sitoh; Kang Sim
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

Review 10.  NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review.

Authors:  Ruey-Horng Shih; Chen-Yu Wang; Chuen-Mao Yang
Journal:  Front Mol Neurosci       Date:  2015-12-18       Impact factor: 5.639

View more
  4 in total

1.  Time and frequency dependent changes in resting state EEG functional connectivity following lipopolysaccharide challenge in rats.

Authors:  Matthew A Albrecht; Chloe N Vaughn; Molly A Erickson; Sarah M Clark; Leonardo H Tonelli
Journal:  PLoS One       Date:  2018-11-12       Impact factor: 3.240

Review 2.  Hippocampal regenerative medicine: neurogenic implications for addiction and mental disorders.

Authors:  Lee Peyton; Alfredo Oliveros; Doo-Sup Choi; Mi-Hyeon Jang
Journal:  Exp Mol Med       Date:  2021-03-30       Impact factor: 8.718

3.  Lipopolysaccharide Increases Cortical Kynurenic Acid and Deficits in Reference Memory in Mice.

Authors:  Lee Peyton; Alfredo Oliveros; Maximilian Tufvesson-Alm; Lilly Schwieler; Phillip Starski; Göran Engberg; Sopie Erhardt; Doo-Sup Choi
Journal:  Int J Tryptophan Res       Date:  2019-12-17

4.  Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial.

Authors:  Vincent Millischer; Matthias Heinzl; Anthi Faka; Michael Resl; Ada Trepci; Carmen Klammer; Margot Egger; Benjamin Dieplinger; Martin Clodi; Lilly Schwieler
Journal:  J Neuroinflammation       Date:  2021-07-17       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.